Target
CYP17A1
32 abstracts
Abstract
ODM-209, a CYP 11A1 inhibitor in patients with mCRPC: Results from the STESIDES phase 1 study.Org: Rigshospitalet University Hospital of Copenhagen, HUCH, Finland, Tampere University Hospital (TAYS), Espoo,
Abstract
Phase 1 trial of mevrometostat (PF-06821497), a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in castration-resistant prostate cancer (CRPC).Org: Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, Private Medical Institution, Euromed service, St Petersburg, Russian Federation, START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain, Department Of Medicine, Norwalk Hospital, Nuvance Health, Norwalk, CT, Pfizer Inc., Collegeville, PA,
Abstract
A phase 1b study of PSCA CAR T cells plus or minus radiation for the treatment of patients with PSCA+ metastatic castration-resistant prostate cancer.Org: Michelson Center for Convergent Bioscience,
Abstract
ALADDIN: Evaluation of darolutamide addition to androgen deprivation therapy and radiation therapy in newly diagnosed prostate cancer with pelvic lymph nodes metastases.Org: Georges Pompidou European Hospital, Pôle santé Léonard de Vinci, Centre d’oncologie et radiothérapie, ROC37, Finisterian Center of Radiotherapy and Oncology,
Abstract
Abiraterone with discontinuation of gonadotropin-releasing hormone (GnRH) analogues in patients (pts) with metastatic prostate cancer (PC): A single arm, phase II study.Org: Montefiore Medical Center Department of Surgery,
Abstract
PROact: A prospective phase II study to evaluate olaparib plus abiraterone and prednisone combination therapy in patients with metastatic hormone sensitive prostate cancer with HRR gene mutation.Org: Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Institute of Urology, Nanjing University, Nanjing, China,
Abstract
Overall survival from PANTHER: A multicenter trial of apalutamide, abiraterone acetate plus prednisone in Black and White patients with metastatic castration-resistant prostate cancer (mCRPC).Org: Chesapeake Urology Research Associates, Duke Cancer Network,
Abstract
CYP11A1 inhibitor MK-5684 versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after 1 prior NHA: Phase 3 MK-5684-004 study.Org: Roanoke, University Hospital Freiburg,
Abstract
Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with new hormonal agents in patients with metastatic castration-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01).Org: British Columbia Cancer Agency (BCCA), Vancouver Cancer Centre, Vancouver, BC, Canada, Huntsman Cancer Institute, Salt Lake City, UT, Cancer Institute Center for Prostate and Urologic Cancer, Duke University Medical Center, Durham, NC, Urologicum Duisburg, Duisburg, Germany, Centre Hospitalier de Quimper, Institut de Cancérologie de Cornouaille (ICC), Brest, France, Kagawa University, Kagawa, Japan, Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey, Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, AstraZeneca, Gaithersburg, MD, AstraZeneca, Cambridge, United Kingdom, Peter MacCallum Cancer Centre, Melbourne, Australia,
Abstract
Prevalence of polypharmacy, drug-drug interactions, and inappropriate prescription in elderly patients with urological cancers.Org: Hospital Universitario Marques Valdecilla, HUMV,
Abstract
A systematic literature review and indirect treatment comparison of PARP inhibitors in combination with next-generation hormonal agents in BRCA-mutated metastatic castration‑resistant prostate cancer.Org: Mtech Access,
Abstract
KPG-121, a novel cereblon modulator, in patients with metastatic castration resistant prostate cancer: Results of a phase I multiple ascending dose study.Org: University of Virginia Comprehensive Cancer Center, New York Cancer and Blood Specialists, Comprehensive Cancer Centers of Nevada, Kangpu Biopharmaceuticals,
Abstract
Utidelone for heavily pretreated metastatic castration-resistant prostate cancer after failing docetaxel treatment: An open-label, single-arm, phase II trial.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Beijing Biostar Pharmaceuticals,
Abstract
Interim analysis of clinical data and reasons for initiating relugolix on a cohort of US patients: The OPTYX study.Org: University Hospitals Seidman Cancer Center and Case Western Reserve University, University of California, San Diego Health, Northwestern University Feinberg School of Medicine, Department of Urology, Chicago, IL, Chesapeake Urology, Sumitomo Pharma America,
Abstract
Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC).Org: Prostate Cancer Foundation, University of Minnesota Masonic Cancer Center, Minneapolis, MN, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Mayo Clinic,
Abstract
Real-world safety and effectiveness of radium-223 (223Ra) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated in the US: The non-interventional REASSURE study.Org: Roswell Park Cancer Institute, Advanced Radiation Centers of New York, Bayer HealthCare Pharmaceuticals Inc., Bayer Consumer Care AG,
Abstract
Concurrent chemo-hormonal therapy of enzalutamide (ENZ) and cabazitaxel (CAB) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final analysis of objective response rate (ORR), radiographic progression-free survival (rPFS), and overall survival (OS).Org: OHSU Knight Cancer Institute, Portland, OR, Boston University Chobanian & Avedisian School of Medicine, Exact Sciences Corporation, Oregon Health & Science University, University of Washington; Fred Hutchinson Cancer Center,
Abstract
Tumor heterogeneity and treatment response assessment using next generation imaging and liquid biopsy in patients with metastatic castration resistant prostate cancer receiving abiraterone (ANGELA): A single-center prospective observational trial.Org: Fudan University Shanghai Cancer Center, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China,
Abstract
Association of dynamic changes in serological markers with survival in de novo metastatic hormone-sensitive prostate cancer.Org: Rush University Medical Center, Case Western Reserve University School of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, UCLA Department of Radiation Oncology,
Abstract
An analysis to inform the timing of docetaxel use leveraging data from the United States Veterans Administration on patients with metastatic castration-sensitive prostate cancer (mCSPC).Org: Columbia University Medical Center, University of Nebraska Medical Center, Institute of Molecular Biology, Bulgarian Academy of Sciences, Columbia University Herbert Irving Comprehensive Cancer Center, James Peters Bronx Veterans Affairs Medical Center,
Abstract
Comparing the efficacy of abiraterone and enzalutamide in United States veterans with metastatic castration-sensitive prostate cancer (mCSPC) by estimating rates of tumor growth (g-rate).Org: University of Nebraska Medical Center, Columbia University Medical Center, Institute of Molecular Biology, Bulgarian Academy of Sciences, James J. Peters VA Medical Center, Suny Downstate Health Sciences University,
Abstract
A phase (Ph) I/II trial of abiraterone acetate in combination with tildrakizumab (anti-IL23 monoclonal antibody) in patients with metastatic castration-resistant prostate cancer (mCRPC).Org: Institute of Cancer Research, London, United Kingdom, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, Department of Oncology, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom, Centre For Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, United Kingdom, Department of Oncology & Metabolism, University of Sheffield and Department of Oncology, Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, United Kingdom,
Abstract
Enzalutamide vs abiraterone in patients with prostate cancer with and without type 2 diabetes mellitus.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Thomas Jefferson University, Division of Biostatistics, Department of Data Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, Department of Pharmacology & Experimental Therapeutics, College of Computing and Informatics,
Abstract
CABIOS trial: A phase Ib study of cabozantinib and nivolumab in combination with abiraterone in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC).Org: Washington University School of Medicine in St Louis, Saint Lukes Hospital,
Abstract
Feasibility of daily physical activity monitoring and associations with treatment toxicity in older adults with metastatic prostate cancer.Org: University Health Network, Princess Margaret Cancer Centre, National Institute of Medical Sciences and Nutrition Salvador Zubirán, University of Toronto, Odette Cancer Centre,
Abstract
Survival of de novo metastatic hormone sensitive prostate cancer in US Veterans based on treatment and PSA at diagnosis.Org: Saint Louis University School of Medicine, University of Washington Medical Center, Fred Hutchinson Cancer Research Center, St. Louis University, Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine,
Abstract
Impact of social determinants of health (SDOH) measures on prescribing advanced androgen blockade (AAB) in patients with metastatic hormone sensitive prostate cancer (mHSPC).Org: US Oncology Network, New York Oncology Hematology PC, Ontada,
Abstract
3D open-top light-sheet microscopy and 3D microdissection of neuoadjuvant-treated primary prostate cancer reveals latent subclonal mutations.Org: University of Washington and Fred Hutchinson Cancer Research Centre, Allen Brain Institute, Fred Hutchinson Cancer Center/Division of Hematology and Oncology,
Abstract
Real world utilization and outcomes of immunotherapy regimens in metastatic castration resistant prostate cancer (mCRPC).Org: Tisch Cancer Institute, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY,
Abstract
Cardiovascular comorbidities and cardiovascular events in patients with metastatic prostate cancer.Org: Laboratoire Toxicomed, University of Tlemcen, Tidjani Damerdji Teaching Hospital, CHU Tlemcen,
Abstract
The association between antibiotics administration and outcomes in men with chemotherapy-naive metastatic castration-resistant prostate cancer: Secondary analysis of two randomized clinical trials.Org: Fudan University Shanghai Cancer Center, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China,
Abstract
Efficacy of PARP inhibitors in patients with metastatic castration resistant prostate carcinoma: A meta-analysis of phase III randomized controlled trials.Org: Community Hospital of San Bernardino, Abbott Northwestern Hospital, SSM St Mary's hospital, University of California Riverside, SSM St Louis University hospital,